CN111227349A - Bactericidal and antiviral mask - Google Patents
Bactericidal and antiviral mask Download PDFInfo
- Publication number
- CN111227349A CN111227349A CN202010119329.5A CN202010119329A CN111227349A CN 111227349 A CN111227349 A CN 111227349A CN 202010119329 A CN202010119329 A CN 202010119329A CN 111227349 A CN111227349 A CN 111227349A
- Authority
- CN
- China
- Prior art keywords
- fullerene
- mask
- derivative
- derivatives
- interlayer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
- A41D13/1192—Protective face masks, e.g. for surgical use, or for use in foul atmospheres with antimicrobial agent
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D31/00—Materials specially adapted for outerwear
- A41D31/04—Materials specially adapted for outerwear characterised by special function or use
- A41D31/30—Antimicrobial, e.g. antibacterial
- A41D31/305—Antimicrobial, e.g. antibacterial using layered materials
Abstract
The invention discloses a sterilizing and antiviral mask, and belongs to the technical field of medical instruments. The mask contains fullerene and derivatives, the hydrophobic surfaces of the fullerene and the derivatives can easily interact with microbial cell membrane lipids and can be inserted into membranes to induce cell membrane damage, and interact with intracellular biomacromolecules, so that excellent antibacterial and antiviral activities are shown, and the bactericidal and antiviral effects of the mask can be enhanced.
Description
Technical Field
The invention belongs to the technical field of medical instruments, and particularly relates to a sterilizing and antiviral mask.
Background
In recent years, the air quality is continuously reduced, industrial waste gas such as particulate matters, sulfur dioxide and the like in the air seriously harm the health of people, various viruses and bacteria are transmitted by taking the air as a medium, the influence on the health of people is not negligible, and the serious condition even threatens the life of people.
The mask is a daily protective sanitary article, is covered outside the mouth and the nose of a person, and can adsorb dust particles in the air around the oral cavity and the nasal cavity and filter pathogens. In the present society, the mask has very wide application in the industrial production fields of medicine and health, precision processing, food and drug industry, closed mining and the like.
Most of the existing protective and medical masks are non-woven fabric masks, and the filter layers arranged between the inner and outer non-woven fabric layers are mainly used for blocking particulate matters or pathogenic bacteria and adsorbing pollutants by static electricity. At present, most of masks which circulate in the market are provided with melt-blown cloth (namely polypropylene material) in the middle as a filter membrane material, and higher masks improve the purification effect by increasing the number of layers of the melt-blown cloth. However, the improvement of the purification capacity is limited by simply increasing the number of layers of the meltblown fabric, on one hand, the components of pollutants in the air are complex, the pollutants have differences in particle size, chargeability and the like, the meltblown fabric is not suitable for all kinds of pollutants, and on the other hand, if the meltblown fabric is wrapped too tightly, the breathing and the comfort level are affected.
In addition, most of the existing masks isolate pollutants and pathogens only by filtration and adsorption, and are difficult to achieve good isolation effect on infectious germs and viruses which are easy to be transmitted through media such as air and the like, because the size of the viruses is only 20-30nm, the aperture of the micron-sized mask is thousands of times larger than that of the viruses, and the probability of pathogenic microorganisms passing through the aperture is quite large; even if bacteria or viruses can be blocked by the mask, since the mask itself has no bactericidal and antiviral functions, the bacteria or viruses can be kept on the mask for several hours or even tens of hours. Therefore, the development of a mask with high bactericidal and antiviral effects is urgently needed.
Disclosure of Invention
1. Technical problem to be solved by the invention
The invention aims to solve the problems that the traditional mask has poor filtering effect and cannot be sterilized well.
2. Technical scheme
In order to achieve the purpose, the technical scheme provided by the invention is as follows:
the invention relates to a bactericidal and antiviral mask, which contains fullerene and derivatives.
Preferably, the fullerene and the derivative are C60And derivatives thereof or C70And derivatives thereof.
Preferably, a fullerene and derivative interlayer is arranged in the mask body of the mask, and the interlayer is non-woven fabric dipped or sprayed with fullerene and derivative suspension with the mass fraction of 0.1-10%.
Preferably, one side or two sides of the fullerene and derivative interlayer are provided with non-woven fabric layers.
Preferably, a filtering layer is further arranged between the fullerene and derivative interlayer and the non-woven fabric layer.
3. Advantageous effects
Compared with the prior art, the technical scheme provided by the invention has the following beneficial effects:
the bactericidal and antiviral mask contains fullerene and derivatives, and the hydrophobic surfaces of the fullerene and the derivatives can easily interact with microbial cell membrane lipids and can be inserted into the membrane to induce cell membrane damage and interact with biological macromolecules in cells, so that the bactericidal and antiviral mask shows excellent antibacterial and antiviral activities and can strengthen the bactericidal and antiviral effects of the mask.
Drawings
FIG. 1 shows a fullerene-containing compound C of the present invention60A schematic diagram of the results of the sterilization test of the compound mask;
FIG. 2 shows a fullerene-containing compound C according to the present invention60The antivirus test result of the compound mask is shown in a schematic diagram;
FIG. 3 shows a fullerene-containing compound C according to the present invention70A schematic diagram of the results of the sterilization test of the compound mask;
FIG. 4 shows a fullerene-containing compound C according to the present invention70The results of the antiviral test of the compound mask are shown schematically.
Detailed Description
In order to facilitate an understanding of the invention, the invention will now be described more fully hereinafter with reference to the accompanying drawings, in which several embodiments of the invention are shown, but which may be embodied in many different forms and are not limited to the embodiments described herein, but rather are provided for the purpose of providing a more thorough disclosure of the invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs; the terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention; as used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.
Example 1
Referring to fig. 1-2, the antiseptic and antiviral mask of the present embodiment contains fullerene and derivatives, wherein the fullerene and derivatives are C60And derivatives thereof or C70And/or derivatives thereof, wherein the mask body is provided with a fullerene and derivative interlayer, the interlayer is a non-woven fabric impregnated or sprayed with fullerene and derivative suspension with the mass fraction of 0.1-10%, and the embodiment selects 0.1% of fullerene C60Suspending the solution, soaking the nonwoven fabric for 10min, and drying at 160 deg.C for 5 min. In this embodiment, a non-woven fabric layer is disposed on one side or both sides of the fullerene and derivative interlayer, and a filter layer is disposed between the fullerene and derivative interlayer and the non-woven fabric layer.
Example 2
The antiseptic and antiviral mask of the present embodiment contains fullerene and derivatives, wherein the fullerene and derivatives are C60And derivatives thereof or C70And/or derivatives thereof, wherein the mask body is provided with a fullerene and derivative interlayer, the interlayer is a non-woven fabric impregnated or sprayed with fullerene and derivative suspension with the mass fraction of 0.1-10%, and the embodiment selects fullerene C with the mass fraction of 1%60Suspending the solution, soaking the nonwoven fabric for 10min, and drying at 160 deg.C for 5 min. In this embodiment, a non-woven fabric layer is disposed on one side or both sides of the fullerene and derivative interlayer, and a filter layer is disposed between the fullerene and derivative interlayer and the non-woven fabric layer.
Example 3
The antiseptic and antiviral mask of the present embodiment contains fullerene, derivatives and fullereneAlkene and derivative thereof is C60And derivatives thereof or C70And/or derivatives thereof, wherein the mask body is provided with a fullerene and derivative interlayer, the interlayer is a non-woven fabric impregnated or sprayed with fullerene and derivative suspension with the mass fraction of 0.1-10%, and the embodiment selects fullerene C with the mass fraction of 3%60Suspending the solution, soaking the nonwoven fabric for 10min, and drying at 160 deg.C for 5 min. In this embodiment, a non-woven fabric layer is disposed on one side or both sides of the fullerene and derivative interlayer, and a filter layer is disposed between the fullerene and derivative interlayer and the non-woven fabric layer.
Example 4
The antiseptic and antiviral mask of the present embodiment contains fullerene and derivatives, wherein the fullerene and derivatives are C60And derivatives thereof or C70And/or derivatives thereof, wherein the mask body is provided with a fullerene and derivative interlayer, the interlayer is a non-woven fabric impregnated or sprayed with fullerene and derivative suspension with the mass fraction of 0.1-10%, and the embodiment selects fullerene C with the mass fraction of 5%60Suspending the solution, soaking the nonwoven fabric for 10min, and drying at 160 deg.C for 5 min. In this embodiment, a non-woven fabric layer is disposed on one side or both sides of the fullerene and derivative interlayer, and a filter layer is disposed between the fullerene and derivative interlayer and the non-woven fabric layer.
Example 5
The antiseptic and antiviral mask of the present embodiment contains fullerene and derivatives, wherein the fullerene and derivatives are C60And derivatives thereof or C70And/or derivatives thereof, wherein the mask body is provided with a fullerene and derivative interlayer, the interlayer is a non-woven fabric impregnated or sprayed with fullerene and derivative suspension with the mass fraction of 0.1-10%, and the embodiment selects 10% of fullerene C60Suspending the solution, soaking the nonwoven fabric for 10min, and drying at 160 deg.C for 5 min. Fullerene of this exampleThe non-woven fabric layers are arranged on one side or two sides of the fullerene and derivative interlayer, the non-woven fabric layers are arranged on two sides of the fullerene and derivative interlayer, and the filter layer is further arranged between the fullerene and derivative interlayer and the non-woven fabric layers.
Comparative example
The mask of this comparative example was a mask containing no fullerene/derivative interlayer, and the rest of the structure was the same as described above.
The masks prepared in examples 1 to 5 and comparative examples were subjected to a sterilization test, and the test procedures and results were as follows:
the test strain is staphylococcus aureus, and the test sample is the mask main body in the examples 1-5 and the comparative example. Firstly, preparing a bacterium suspension: a24 h fresh culture of Staphylococcus aureus broth was taken and diluted with peptone-containing phosphate buffer to prepare a suspension of the test concentration for use. Connecting an aerosol generator with a peristaltic pump and an air source, connecting a generator spray nozzle with an air inlet of a pipeline, wherein the pipeline is provided with two sampling ports, one sampling port is connected with a testing mask, and the sampling port is used as an experimental group after being sampled by an air microorganism sampler; the other sampling port is not provided with a mask, and the other sampling port is directly used as positive quality control after being sampled by an air microorganism sampler. And (3) placing the bacterial suspension into a bacterial liquid bottle of an aerosol generator, starting the aerosol generator, and spraying according to the flow rate of 5L/min and the spraying pressure of 1.8kg/cm2 to generate aerosol. Spraying and infecting for 1min, loading a sampling flat plate with the diameter of 90mm into a six-stage sampler, sampling a test mask sample for 2min and sampling positive quality control for 1min according to the sampling flow of 28.3L/min. It was calculated that the mean particle diameter (MPS) of the bacterial aerosol should be (3.0. + -. 0.3) μm and the geometric standard deviation of the bacterial aerosol distribution should not exceed 1.5. And putting the sampling plates into a 37 ℃ incubator for culturing for 48h, counting the number of colonies (cfu) of each sampling plate, enabling the results of the 4 th and 5 th levels of sampling to meet the particle size requirement in the standard, correcting by using a correction table, converting the concentration of the bacterial aerosol into cfu/m3, and calculating the filtering efficiency according to the concentrations of the bacterial aerosol before and after filtering. The formula for calculating the filtering efficiency of the mask bacteria is BFE (C-T)/C multiplied by 100% (wherein C is the positive quality control aerosol concentration, and T is the aerosol concentration of the test sample). As shown in fig. 1, it is understood that the masks of examples 1 to 5 have significant sterilization effects, and the bacterial filtration efficiencies are all greater than 96% and better than those of the comparative examples.
The masks prepared in examples 1 to 5 and comparative examples were subjected to an antiviral test, and the test procedures and results were as follows:
the antiviral activity of the antiviral test was carried out by the antiviral test method for fiber products ISO 18184. In summary, the test virus was influenza A virus (H3N2), the host cell was MDCK cell, the test sample was the mask body of examples 1 to 5 and comparative example, the eluate was SCDLP medium, the storage condition was 25 ℃ for 2 hours, and the infectivity measurement method was plaque measurement. Specifically, first, a virus suspension is prepared: the host cells were infected with the virus, cell debris was removed by centrifugation after culture, and the virus suspension was diluted to (2. + -. 1). times.107 PFU/mL using sterile physiological saline. 0.2mL of the test virus suspension was injected into each test sample, left at 25 ℃ for 2 hours, 20mL of the eluate was added, stirred with a vortex mixer for 10min, and finally, the virus infectivity was measured by plaque assay. As shown in fig. 2, it can be seen from the test results that the masks of examples 1 to 5 have a significant antiviral effect, and the antiviral activity value is 4.0 or more, and the effect of reducing the effect of viruses to 1 ten-thousandth or less can be obtained.
Example 6
The antiseptic and antiviral mask of the present embodiment contains fullerene and derivatives, wherein the fullerene and derivatives are C60And derivatives thereof or C70And/or derivatives thereof, wherein the mask body is provided with a fullerene and derivative interlayer, the interlayer is a non-woven fabric impregnated or sprayed with fullerene and derivative suspension with the mass fraction of 0.1-10%, and the embodiment selects 0.1% of fullerene C70Suspending the solution, soaking the nonwoven fabric for 10min, and drying at 160 deg.C for 5 min. In this embodiment, a non-woven fabric layer is disposed on one side or both sides of the fullerene and derivative interlayer, and a filter layer is disposed between the fullerene and derivative interlayer and the non-woven fabric layer.
Example 7
The antiseptic and antiviral mask of the present embodiment contains fullerene and derivatives, wherein the fullerene and derivatives are C60And derivatives thereof or C70And/or derivatives thereof, wherein the mask body is provided with a fullerene and derivative interlayer, the interlayer is a non-woven fabric impregnated or sprayed with fullerene and derivative suspension with the mass fraction of 0.1-10%, and the embodiment selects fullerene C with the mass fraction of 1%70Suspending the solution, soaking the nonwoven fabric for 10min, and drying at 160 deg.C for 5 min. In this embodiment, a non-woven fabric layer is disposed on one side or both sides of the fullerene and derivative interlayer, and a filter layer is disposed between the fullerene and derivative interlayer and the non-woven fabric layer.
Example 8
The antiseptic and antiviral mask of the present embodiment contains fullerene and derivatives, wherein the fullerene and derivatives are C60And derivatives thereof or C70And/or derivatives thereof, wherein the mask body is provided with a fullerene and derivative interlayer, the interlayer is a non-woven fabric impregnated or sprayed with fullerene and derivative suspension with the mass fraction of 0.1-10%, and the embodiment selects fullerene C with the mass fraction of 3%70Suspending the solution, soaking the nonwoven fabric for 10min, and drying at 160 deg.C for 5 min. In this embodiment, a non-woven fabric layer is disposed on one side or both sides of the fullerene and derivative interlayer, and a filter layer is disposed between the fullerene and derivative interlayer and the non-woven fabric layer.
Example 9
The antiseptic and antiviral mask of the present embodiment contains fullerene and derivatives, wherein the fullerene and derivatives are C60And derivatives thereof or C70And/or derivatives thereof, wherein the mask body of the mask is provided with a fullerene and derivative interlayer, and the interlayer is a non-woven fabric impregnated or sprayed with fullerene and derivative suspension with the mass fraction of 0.1-10%Selecting 5% fullerene C70Suspending the solution, soaking the nonwoven fabric for 10min, and drying at 160 deg.C for 5 min. In this embodiment, a non-woven fabric layer is disposed on one side or both sides of the fullerene and derivative interlayer, and a filter layer is disposed between the fullerene and derivative interlayer and the non-woven fabric layer.
Example 10
The antiseptic and antiviral mask of the present embodiment contains fullerene and derivatives, wherein the fullerene and derivatives are C60And derivatives thereof or C70And/or derivatives thereof, wherein the mask body is provided with a fullerene and derivative interlayer, the interlayer is a non-woven fabric impregnated or sprayed with fullerene and derivative suspension with the mass fraction of 0.1-10%, and the embodiment selects 10% of fullerene C70Suspending the solution, soaking the nonwoven fabric for 10min, and drying at 160 deg.C for 5 min. In this embodiment, a non-woven fabric layer is disposed on one side or both sides of the fullerene and derivative interlayer, and a filter layer is disposed between the fullerene and derivative interlayer and the non-woven fabric layer.
The masks prepared in examples 6 to 10 and comparative examples were subjected to a sterilization test, and the test procedures and results were as follows:
the test strain is staphylococcus aureus, and the test sample is the mask main body in the embodiment 6-10 and the comparative example. Firstly, preparing a bacterium suspension: a24 h fresh culture of Staphylococcus aureus broth was taken and diluted with peptone-containing phosphate buffer to prepare a suspension of the test concentration for use. Connecting an aerosol generator with a peristaltic pump and an air source, connecting a generator spray nozzle with an air inlet of a pipeline, wherein the pipeline is provided with two sampling ports, one sampling port is connected with a testing mask, and the sampling port is used as an experimental group after being sampled by an air microorganism sampler; the other sampling port is not provided with a mask, and the other sampling port is directly used as positive quality control after being sampled by an air microorganism sampler. And (3) placing the bacterial suspension into a bacterial liquid bottle of an aerosol generator, starting the aerosol generator, and spraying according to the flow rate of 5L/min and the spraying pressure of 1.8kg/cm2 to generate aerosol. Spraying and infecting for 1min, loading a sampling flat plate with the diameter of 90mm into a six-stage sampler, sampling a test mask sample for 2min and sampling positive quality control for 1min according to the sampling flow of 28.3L/min. It was calculated that the mean particle diameter (MPS) of the bacterial aerosol should be (3.0. + -. 0.3) μm and the geometric standard deviation of the bacterial aerosol distribution should not exceed 1.5. And putting the sampling plates into a 37 ℃ incubator for culturing for 48h, counting the number of colonies (cfu) of each sampling plate, enabling the results of the 4 th and 5 th levels of sampling to meet the particle size requirement in the standard, correcting by using a correction table, converting the concentration of the bacterial aerosol into cfu/m3, and calculating the filtering efficiency according to the concentrations of the bacterial aerosol before and after filtering. The formula for calculating the filtering efficiency of the mask bacteria is BFE (C-T)/C multiplied by 100% (wherein C is the positive quality control aerosol concentration, and T is the aerosol concentration of the test sample). As shown in fig. 3, it is understood that the masks of examples 6 to 10 have significant sterilization effects, and the bacterial filtration efficiencies are all greater than 96% and better than those of the comparative examples.
The masks prepared in examples 6 to 10 and comparative examples were subjected to an antiviral test, and the test procedures and results were as follows:
the antiviral activity of the antiviral test was carried out by the antiviral test method for fiber products ISO 18184. In the test outline, the test virus was influenza A virus (H3N2), the host cell was MDCK cell, the test samples were SCDLP medium in examples 6 to 10 and comparative example, the eluate was left at 25 ℃ for 2 hours, and the infectivity measurement method was plaque measurement. Specifically, first, a virus suspension is prepared: the host cells were infected with the virus, cell debris was removed by centrifugation after culture, and the virus suspension was diluted to (2. + -. 1). times.107 PFU/mL using sterile physiological saline. 0.2mL of the test virus suspension was injected into each test sample, left at 25 ℃ for 2 hours, 20mL of the eluate was added, stirred with a vortex mixer for 10min, and finally, the virus infectivity was measured by plaque assay. As shown in fig. 4, it can be seen from the test results that the masks of examples 6 to 10 have a significant antiviral effect, and the antiviral activity value is 4.0 or more, and the effect of reducing the effect of viruses to 1 ten-thousandth or less can be obtained.
The above-mentioned embodiments only express a certain implementation mode of the present invention, and the description thereof is specific and detailed, but not construed as limiting the scope of the present invention; it should be noted that, for those skilled in the art, without departing from the concept of the present invention, several variations and modifications can be made, which are within the protection scope of the present invention; therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (5)
1. A sterilization antiviral mask is characterized in that: the mask contains fullerene and derivatives.
2. The antiseptic and antiviral mask as claimed in claim 1, wherein: the fullerene and the derivative are C60And derivatives thereof or C70And derivatives thereof.
3. The antiseptic and antiviral mask as claimed in claim 1, wherein: the mask body of the mask is internally provided with a fullerene and derivative interlayer, and the interlayer is non-woven fabric dipped or sprayed with fullerene and derivative suspension with the mass fraction of 0.1-10%.
4. The antiseptic and antiviral mask according to claim 3, wherein: and a non-woven fabric layer is arranged on one side or two sides of the fullerene and derivative interlayer.
5. The antiseptic and antiviral mask as claimed in claim 4, wherein: and a filtering layer is also arranged between the fullerene and derivative interlayer and the non-woven fabric layer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010119329.5A CN111227349A (en) | 2020-02-26 | 2020-02-26 | Bactericidal and antiviral mask |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010119329.5A CN111227349A (en) | 2020-02-26 | 2020-02-26 | Bactericidal and antiviral mask |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111227349A true CN111227349A (en) | 2020-06-05 |
Family
ID=70868481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010119329.5A Pending CN111227349A (en) | 2020-02-26 | 2020-02-26 | Bactericidal and antiviral mask |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111227349A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN203342543U (en) * | 2013-05-31 | 2013-12-18 | 东木奥森科技（天津）有限公司 | Air purification filter net |
| CN103965570A (en) * | 2014-05-05 | 2014-08-06 | 北京吉安信科技有限公司 | Preparation method for composite material of hydrophilic fullerene derivative and metallic oxide |
| CN105266238A (en) * | 2015-11-25 | 2016-01-27 | 常州纳美生物科技有限公司 | Anti-haze green mouth mask based on oxidized graphene and manufacturing method |
| CN107626218A (en) * | 2017-10-24 | 2018-01-26 | 陕西省石油化工研究设计院 | A kind of preparation method of graphene oxide/nonwoven fabrics composite film |
| KR20180095492A (en) * | 2018-08-20 | 2018-08-27 | 송남강 | Multi-functional mask |
| CN109701504A (en) * | 2018-12-17 | 2019-05-03 | 宿迁市美达净化科技有限公司 | A kind of graphene antibacterial mask filtering material and its preparation method and application |
-
2020
- 2020-02-26 CN CN202010119329.5A patent/CN111227349A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN203342543U (en) * | 2013-05-31 | 2013-12-18 | 东木奥森科技（天津）有限公司 | Air purification filter net |
| CN103965570A (en) * | 2014-05-05 | 2014-08-06 | 北京吉安信科技有限公司 | Preparation method for composite material of hydrophilic fullerene derivative and metallic oxide |
| CN105266238A (en) * | 2015-11-25 | 2016-01-27 | 常州纳美生物科技有限公司 | Anti-haze green mouth mask based on oxidized graphene and manufacturing method |
| CN107626218A (en) * | 2017-10-24 | 2018-01-26 | 陕西省石油化工研究设计院 | A kind of preparation method of graphene oxide/nonwoven fabrics composite film |
| KR20180095492A (en) * | 2018-08-20 | 2018-08-27 | 송남강 | Multi-functional mask |
| CN109701504A (en) * | 2018-12-17 | 2019-05-03 | 宿迁市美达净化科技有限公司 | A kind of graphene antibacterial mask filtering material and its preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| 胡桢: "《新型高分子合成与制备工艺》", 31 May 2014, 哈尔滨工业大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vaze et al. | Inactivation of common hospital acquired pathogens on surfaces and in air utilizing engineered water nanostructures (EWNS) based nano-sanitizers | |
| CN111467956A (en) | Modified nano titanium dioxide photocatalyst oral cavity examination room droplet and aerosol suction device | |
| Rengasamy et al. | Evaluation of the survivability of MS2 viral aerosols deposited on filtering face piece respirator samples incorporating antimicrobial technologies | |
| CN111514479A (en) | Microorganism disinfection type silver-carrying mask | |
| CN102389743A (en) | Formula of medical bacteriostatic humidifying solution | |
| CN201111129Y (en) | Totally-enclosed bill counter with dust removing and sterilizing apparatus | |
| CN101658705B (en) | Medical humidification fluid with bacteria resistance function | |
| US11857001B2 (en) | Antipathogenic face mask | |
| CN111227349A (en) | Bactericidal and antiviral mask | |
| CN112641147A (en) | Recyclable mask, preparation method and recycling method | |
| CN104498443A (en) | Acinetobacter baumannii phage and application thereof | |
| CN111449855A (en) | Negative pressure high-efficiency particle air filtering, purifying and isolating platform for infectious disease infection source | |
| Kim et al. | Survival of microorganisms on antimicrobial filters and the removal efficiency of bioaerosols in an environmental chamber | |
| CN212619088U (en) | Air isolation type clean screen | |
| Guo et al. | Inactivation of airborne pathogenic microorganisms by plasma-activated nebulized mist | |
| Arnold | A new surgical mask: A bacteriologic air filter | |
| CN114190632A (en) | Antibacterial breathable mask and preparation method thereof | |
| WO2021211697A1 (en) | Antipathogenic face mask | |
| Yang et al. | Study on an air filter material immobilized with bio-antimicrobials | |
| CN111202101A (en) | Anti-fogging disposable mask preparation liquid and preparation method thereof | |
| CN116114711B (en) | Indoor environment microorganism cleaning agent and application thereof | |
| Nur et al. | A successful elimination of Indonesian SARS-CoV-2 variants and airborne transmission prevention by cold plasma in fighting COVID-19 pandemic: A preliminary study | |
| CN215583216U (en) | Mask with sterilization and antivirus functions | |
| CN110129282A (en) | Vibrio alginolyticus bacteriophage and bacteriophage composition and its application | |
| CN109602736A (en) | A kind of bactericidal agent and its sterilization method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200605 |
|
| RJ01 | Rejection of invention patent application after publication |